Clinical Trial Update: The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial update on cobitolimod for moderate to severe active left-sided ulcerative colitis; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• cobitolimod (cobitolimod)

Snippet

Sponsor: InDex Pharmaceuticals | Conditions: Ulcerative Colitis | Phase 3 | Status: TERMINATED